Curated News
By: NewsRamp Editorial Staff
April 29, 2026

Evotec Nominates Dr. Wolfgang Hofmann to Board, Reaches Deal with MAK Capital

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Evotec strengthens governance with independent board nomination and MAK Capital cooperation, enhancing shareholder value.
  • Evotec nominates Dr. Wolfgang Hofmann to Supervisory Board and expands board to seven members, with MAK Capital agreeing to voting commitments.
  • Evotec's commitment to open dialogue with shareholders and enhanced oversight supports long-term success in drug discovery.
  • MAK Capital, a key shareholder, cooperates with Evotec after constructive discussions, backing board expansion and transformation plans.

Impact - Why it Matters

This news matters because it signals Evotec's commitment to strengthening corporate governance and shareholder alignment during a critical transformation phase. The nomination of an independent director with deep industry expertise and the cooperation agreement with a major investor like MAK Capital suggest enhanced oversight and strategic focus, which could lead to improved performance and value creation for shareholders and stakeholders in the biotech ecosystem.

Summary

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has announced the nomination of Dr. Wolfgang Hofmann as an independent member of its Supervisory Board, pending approval at the upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM will also vote on the previously announced nomination of Dieter Weinand as Chairman and a proposed expansion of the Supervisory Board from six to seven members. This move is part of Evotec’s broader strategy to strengthen oversight and governance capabilities as it continues its transformation to drive long-term shareholder value.

In parallel, Evotec has reached a cooperation agreement with MAK Capital Fund LP, a key shareholder, following constructive discussions. Under the agreement, MAK Capital has committed to customary voting and cooperation provisions, reflecting Evotec’s dedication to open shareholder dialogue. Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board, expressed confidence that Dr. Hofmann’s appointment would bring additional industry, scientific, and governance expertise, complementing the existing board structure. Michael A. Kaufman, CEO of MAK Capital, welcomed the nomination and reaffirmed continued collaboration to support Evotec’s transformation.

Evotec, a life science company pioneering drug discovery and development, integrates breakthrough science with AI-driven innovation and advanced technologies. Its expertise spans small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms like Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. The company partners with top 20 pharma firms, over 800 biotechs, and academic institutions. With a team of over 4,500 experts operating from sites in Europe and the U.S., Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. For more details, visit www.evotec.com and follow on LinkedIn.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Evotec Nominates Dr. Wolfgang Hofmann to Board, Reaches Deal with MAK Capital

blockchain registration record for this content.